# Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

> **NCT02303366** · PHASE1 · COMPLETED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 15 (actual)

## Conditions studied

- Breast Neoplasms
- Bone Neoplasms

## Interventions

- **RADIATION:** Stereotactic Ablative Body Radiosurgery (SABR)
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02303366
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303366, "Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02303366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*